Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals's lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders.
Subscribe to our email newsletter
Roche’s exercise of its option triggers a $6 million milestone payment and entitles Memory to future payments upon the achievement of additional milestones and royalties on product sales, including a $17 million milestone payment upon the completion of the ongoing Phase IIa study in cognitive impairment associated with schizophrenia (CIAS). In addition, Memory Pharmaceuticals retains an option to co-promote MEM 3454 in the US.
Vaughn Kailian, president and CEO of Memory, said: “We have aggressively advanced MEM 3454 through early-stage clinical trials, including a positive Phase IIa trial in Alzheimer’s disease.
“We believe that Roche’s continued commitment to the program, together with its expertise in later-stage clinical development and commercialization, will provide the support and capabilities to realize the full potential of this compound.”